RxDoctor Payments Data

Elisabeth Butler

Gerontology · Providence, RINPI 1588196133

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 10 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 9 manufacturers, the largest accounting for just 15.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $462, 7.4 times the $62 reported in 2021.

$874in general payments, 2019–2025

Across 10 payments — averaging $87.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$138
  • Lilly USA, LLC$125
  • Otsuka America Pharmaceutical, Inc.$121
  • Boehringer Ingelheim$114
  • Idorsia Pharmaceuticals US Inc$100
  • Neurocrine Biosciences, Inc.$89
  • plus $187 from 3 others

What the payments were for

  • Food & beverage$874100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$874 in reported general payments places this provider in the 65th percentile of 39 gerontology providers in Rhode Island.

See all gerontology providers in Rhode Island

Medicare billing

Part B allowed, 2024
$325,150
Medicare patients
599
Services billed
3,612

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate12$43,976
EliquisApixaban108$32,270
Sevelamer Carbonate17$8,676
JardianceEmpagliflozin26$7,344
MyrbetriqMirabegron23$5,944
Arnuity ElliptaFluticasone Furoate14$4,637
TradjentaLinagliptin16$4,255
Paliperidone ErPaliperidone13$2,726
Memantine Hcl37$2,522
Atorvastatin Calcium107$2,188
Risperidone41$1,690
Insulin Lispro Protamine MixInsulin Lispro Protamin/Lispro14$1,606
Mirtazapine47$1,551
Chlorpromazine Hcl24$1,323
Levothyroxine Sodium77$1,270

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$114$11,60042 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 39 gerontology providers in Rhode Island.

Other gerontology in Providence

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →